Literature DB >> 7589510

Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro.

Y Ezumi1, H Takayama, M Okuma.   

Abstract

We investigated in vitro effects of recombinant human thrombopoietin (TPO), or c-Mpl ligand, on human platelets. TPO induced rapid dose-dependent tyrosine phosphorylation of several proteins. We identified Janus tyrosine kinases, Tyk2 and JAK2, and a member of STAT (signal transducers and activators of transcription) family, STAT3, as the tyrosine-phosphorylated proteins in response to TPO. TPO by itself did not cause platelet aggregation and shape change, but augmented ADP-induced aggregation in a dose-dependent manner. Acetylsalicylic acid inhibited the secondary aggregation enhanced by TPO, but not the TPO-induced potentiation of the primary aggregation. TPO modulates platelet activation possibly through protein-tyrosine phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589510     DOI: 10.1016/0014-5793(95)01072-m

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  29 in total

1.  Two patterns of thrombopoietin signaling suggest no coupling between platelet production and thrombopoietin reactivity in thrombocytopenia-absent radii syndrome.

Authors:  Janine Fiedler; Gabriele Strauss; Martin Wannack; Silke Schwiebert; Kerstin Seidel; Katja Henning; Eva Klopocki; Markus Schmugge; Gerhard Gaedicke; Harald Schulze
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

2.  Prolonged remission from eltrombopag in chronic refractory idiopathic thrombocytopenic purpura.

Authors:  V Noronha; S D Philip; A Joshi; K Prabhash
Journal:  Int J Hematol       Date:  2012-08-01       Impact factor: 2.490

3.  JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation.

Authors:  Rodolphe Besancenot; Damien Roos-Weil; Carole Tonetti; Hadjer Abdelouahab; Catherine Lacout; Florence Pasquier; Christophe Willekens; Philippe Rameau; Yann Lecluse; Jean-Baptiste Micol; Stefan N Constantinescu; William Vainchenker; Eric Solary; Stéphane Giraudier
Journal:  Blood       Date:  2014-08-20       Impact factor: 22.113

Review 4.  Novel chemical attempts at ex vivo hematopoietic stem cell expansion.

Authors:  Yu Zhang; Yingdai Gao
Journal:  Int J Hematol       Date:  2016-02-24       Impact factor: 2.490

Review 5.  Ex vivo expansion of umbilical cord blood: where are we?

Authors:  Omar S Aljitawi
Journal:  Int J Hematol       Date:  2012-03-23       Impact factor: 2.490

6.  Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets.

Authors:  A S Weyrich; D A Dixon; R Pabla; M R Elstad; T M McIntyre; S M Prescott; G A Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

Review 7.  Failing to live up to the fanfare? A personal perspective on obstacles to the clinical development of thrombopoietic agents.

Authors:  R L Basser; C G Begley
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

Review 8.  The pharmacology and clinical application of thrombopoietin receptor agonists.

Authors:  Caizheng Li; Li Zheng
Journal:  Int J Hematol       Date:  2014-09-18       Impact factor: 2.490

9.  A network map of thrombopoietin signaling.

Authors:  Firdous A Bhat; Jayshree Advani; Aafaque Ahmad Khan; Sonali Mohan; Arnab Pal; Harsha Gowda; Prantar Chakrabarti; T S Keshava Prasad; Aditi Chatterjee
Journal:  J Cell Commun Signal       Date:  2018-07-24       Impact factor: 5.782

10.  Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.

Authors:  Connie L Erickson-Miller; Evelyne Delorme; Shin-Shay Tian; Christopher B Hopson; Amy J Landis; Elizabeth I Valoret; Teresa S Sellers; Jon Rosen; Stephen G Miller; Juan I Luengo; Kevin J Duffy; Julian M Jenkins
Journal:  Stem Cells       Date:  2009-02       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.